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PERSPECTIVE
Developmental transcription factors 
in age-related CNS disease: a phoenix 
rising from the ashes?
Few would doubt that understanding the developmental landscape 
from which a mature neuron is derived is essential to understand 
its biology. The temporal and spatial position of a cell from the very 
earliest stages of development predicts the unique combinations of 
growth factors it will subsequently be exposed to. This combination 
of factors determines the transcriptional platform set within the 
cell by its specific combination of transcription factors, who direct 
the show. This, in turn, determines what cell type it will differenti-
ate into, and what connections it will make. How this developmen-
tal platform translates to maintenance of a differentiated neuron in 
an adult brain is less clear.
Most developmental factors control aspects of biology that are 
not required, or even wanted, during or after the differentiation 
process: initiators of DNA synthesis or proliferation are clearly of 
no use to a differentiated neuron, and can certainly evoke damag-
ing effects.
So, why is it commonplace in the adult brain to see the upregu-
lation of developmental factors during stress, trauma, and disease? 
Two potential explanations dominate the debate. Firstly, that there 
is a cellular attempt to rejuvenate (the “phoenix from the ashes”) by 
using the only machinery it ‘knows’ how, or secondly, that, indeed, 
these transcription factors are not simply ‘developmental’, and can 
drive distinct platforms of transcription in different circumstances 
(or “horse for many courses”). These two hypotheses are, of course, 
not necessarily mutually exclusive. 
Regardless of the ‘motive’ many developmental transcription 
factor-encoding genes are recruited in difficult situations in later 
life. One such beast is Pax6, the subject of some of our laboratory’s 
research (Blake et al., 2008; Needhamsen et al., 2014; Thomas et al., 
2016). 
The developmental transcription factor Pax6: The Pax6 gene 
belongs to the highly functionally and structurally conserved Pax 
gene family (Pax1–9) of tissue-specific transcription factors. The 
Pax family are instrumental in development and have a critical role 
in brain regionalisation and specification of subtypes of neurons 
within brain regions. Pax6 is one of the earliest gene products ex-
pressed in the developing embryo. Initially, Pax6 is expressed in the 
neural plate, and after closure of the neural tube it is expressed in 
the lower ventral region except in the most ventral cells of the floor 
plate, acting to ventrally polarize the neural tube.
Pax6 is a key neurogenic factor and a well-accepted neurogenic 
determinant. Indeed, Pax6 is frequently used as a marker of neural 
precursor status. Recent studies have demonstrated that overex-
pression of both Pax6 and another transcription factor, Sox2, is 
sufficient to transdifferentiate fibroblast cells into induced neuronal 
progenitors (Maucksch et al., 2012), in line with it having been 
demonstrated that Pax6 alone induces neuronal specification of 
postnatal forebrain astrocytes (Heins et al., 2002). 
As well as specifying neural progenitor cells, Pax6 also acts in a 
second phase of fate decision-making during development, namely 
during the specification of a subpopulation of neurons. Within 
the developing brain, Pax6 expression is confined to the forebrain, 
optic vesicles and the ventral midbrain (Stoykova and Gruss, 1994). 
Its expression correlates with the appearance of dopaminergic 
neurons of the ventral thalamus (preoptic area, zona incerta and 
periventricular and arcuate nuclei), the mesencephalic tegmentum 
(region of the differentiating substantia nigra) as well as in neurons 
of the dorsolateral part of the reticular substantia nigra (Stoykova 
and Gruss, 1994; Vitalis et al., 2000). 
Over-expression of Pax6 in a variety of cells and circumstanc-
es has provided compelling evidence for a potent role of Pax6 in 
specifying dopamine producing neurons. Its over-expression in 
embryonic day 12 rat ventral mesencephalon neural stem cells 
yields significantly higher tyrosine hydroxylase-expressing neurons 
compared to controls (Spitere et al., 2008). The forced expression 
of Pax6 in rostral migratory stream neural precursors drives newly 
generated periglomerular neurons to assume a tyrosine hydrox-
ylase-positive dopaminergic identity in vivo (Hack et al., 2005). 
Critically, Pax6-deficient neuroblasts transplanted into the subven-
tricular zone of adult wild type mice maintain similar migratory 
and neuronal differentiation capabilities but undergo precocious 
differentiation resulting in cell fate switching and failure to gener-
ate specific dopaminergic neuronal sub-classes (Kohwi et al., 2005). 
More research in this field is certainly required, as there are still 
many anomalies to overcome, as Pax6 suppression has also been 
shown to be beneficial in the generation of a dopaminergic pheno-
type from precursors (Denham et al., 2012). 
In the adult brain: In the adult brain, Pax6 again rears its head, but 
“only” in very specific locations. Very specific indeed, and in keep-
ing with its developmental role – in areas of continued proliferation 
and neurogenesis. Expression is maintained in adult neural progen-
itor cells of the subventricular zone of the olfactory bulb and the 
subgranular zone of the dentate gyrus (Stoykova and Gruss, 1994). 
The “only” in the earlier sentence is in quotation marks as it is nei-
ther the whole truth nor is it nothing but the truth. When people 
have looked more exhaustively and in greater detail, isolated popu-
lations of Pax6-positive cells have been found. In the normal adult 
brain Pax6 expression has also been demonstrated in areas that do 
not undergo overt neurogenesis: the substantia nigra pars reticu-
lata, retina, preoptic area, zona incerta, ventral tegmental area, and 
mesencephalic periaqueductal gray (Stoykova and Gruss, 1994; Vi-
talis et al., 2000). Pax6 is also expressed within certain post-mitotic 
cells of the adult substantia nigra in the human and rodent mid-
brain (Thomas et al., 2016). We have shown that, within the normal 
aging human adult midbrain substantia nigra, a very small number 
of cells express PAX6 protein. In the rat, many of these substantia 
nigra Pax6-positive cells co-label with tyrosine hydroxylase – the 
rate-limiting enzyme in the synthesis of dopamine and is expressed 
in catecholaminergic neurons (White and Thomas, 2012); and thus 
in this area of the adult brain, Pax6 is likely expressed in differenti-
ated dopaminergic neurons. However not all Pax6-positive cells in 
the substantia nigra also expressed tyrosine hydroxylase, and we did 
not observe any co-labelling with astrocyte markers (glial fibrillary 
acidic protein), so this avenue of exploration certainly requires fur-
ther work to generate a comprehensive identity of these cells. 
Disease and damage: In keeping with its role in developmental 
neurogenesis, injury models have suggested that in these adult 
regions Pax6 expression is associated with the generation of new 
neurons in the areas of damage. For example a transient forebrain 
ischemic brain injury induces Pax6 up-regulation in subgranular-
zonal cells (Nakatomi et al., 2002); treatment of a rat Parkinson’s 
disease model with a dopamine receptor agonist increases prolifer-
ation and cell survival in newly generated neurons (Winner et al., 
2009) with concurrent increased expression of Pax6 in these cells; 
a spinal cord injury results in transient up-regulation of Pax6 in 
the ependymal layer (Yamamoto et al., 2001); and the number of 
Pax6-positive cells is markedly increased in the subventricular zone 
following striatal quinolinic acid-induced striatal cell death in rats 
(Jones and Connor, 2011). 
We have also recently shown that, in an animal model of Parkin-
son’s disease, the number of Pax6-positive cells within the midbrain 
substantia nigra increases significantly (Thomas et al., 2016). We 
used the well-characterized rat 6-hydroxydopamine striatal lesion 
model and assessed the number of Pax6-positive cells in the sub-
stantia nigra at time points corresponding to the phase of active cell 
loss (14 days post lesion) and after cell loss has plateaued (28 days 
post lesion).
In this model, the number of Pax6-positive cells is significantly 
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elevated during the phase of active cell loss, and this increase in 
Pax6-positive cells is maintained after cell loss has completed. This 
potentially indicates that the cells that upregulate Pax6 do not die 
throughout this process, and as we have shown that many of these 
Pax6-postive cells are differentiated dopaminergic neurons (tyrosine 
hydroxylase-positive), then we believe this is indeed an interesting 
finding warranting further investigation.
So what about the human disease ‘model’? We obtained post-mor-
tem brain tissue of people who died with Parkinson’s disease and 
have demonstrated that, in comparison to age and sex matched 
controls, the small number of cells expressing PAX6 in the human 
substantia nigra was significantly reduced.
So, what is it doing there? It seems that at least one important 
role that is directed by Pax6 in these adult brain cells is to ensure 
cell survival. Olfactory bulb neurons of 3 month old mice co-ex-
press Pax6 along with markers of terminal dopaminergic differenti-
ation, including tyrosine hydroxylase and the dopamine transporter 
(Ninkovic et al., 2010). The loss of Pax6 expression by Cre-Lox re-
combination results in these neurons undergoing apoptosis, show-
ing that Pax6 is required for the survival of some of these neurons 
(Ninkovic et al., 2010). Some of the genes targeted by Pax6 in this 
process are known; for instance Pax6 mediates survival of olfactory 
bulb neurons via crystallin αA and its loss reduces crystallin αA ex-
pression and induces apoptosis via caspase-3 activation (Ninkovic 
et al., 2010). 
We have also recently shown that PAX6 effectively promotes sur-
vival in a cell culture model of PD – human neuroblastoma-derived 
SH-SY5Y cells differentiated down a dopaminergic lineage using 
retinoic acid and then exposed to dopaminergic-neuron-selective 
neurotoxins (rotenone and 1-methyl-4-phenyl-1,2,3,6-tetrahy-
dropyridine). We induced expression of PAX6 after differentiation 
in this cell culture model and then applied neurotoxic insults and 
measured survival, apoptosis and mitochondrial depolarization. 
PAX6 induction markedly improved how the cells fared in all 
these parameters, indicating that PAX6 over-expression following 
differentiation increases the survival of SH-SY5Y cells exposed to 
dopaminergic-neuron-selective neurotoxins by increasing their 
resistance to both programmed cell death and the effects of ox-
idative stress on mitochondrial health and function. It is worth 
noting that we also observed a significant upregulation of another 
developmental transcription factor gene known to play a role in the 
differentiation and survival of midbrain dopaminergic neurons, 
neurogenin 2, following PAX6 induction (Thomas et al., 2016).
It is intriguing to note that in Parkinson’s disease, the two sub-
stantia nigra areas, the pars compacta and the pars reticulata do not 
share equal vulnerability to developing pathology; the substantia 
nigra pars compacta experiences the highest levels of degeneration, 
with the substantia nigra pars reticulata degenerating later as the 
disease progresses. As we have shown, Pax6 expression occurs in the 
substantia nigra pars reticulata, which could imply a role for Pax6 
in the protection of these dopamine-producing cells. Importantly 
then, Pax6 may have a third function in promoting cell mainte-
nance and/or survival of adult neurons (Blake et al., 2008). 
Conclusion: The phoenix of Greek mythology is a long-lived bird 
that is cyclically regenerated or reborn, obtaining new life by arising 
from the ashes of its predecessor. We do not know the precise func-
tion of our ‘phoenix’ developmental transcription factors in the 
neurobiology of aging brains of humans yet, but it is not entirely 
unlikely that one day we will use them to enable rebirth within the 
ashes of the degenerating central nervous system. 
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